Skip to content
All articles

Multinational phase 1 study of clesitamig for advanced small cell lung cancer and other neuroendocrine carcinomas

Dr. Stephen Fowler
Dr. Stephen Fowler

Small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NEC) have few options after platinum-based chemotherapy and checkpoint inhibition. Delta-like ligand 3 (DLL3), frequently expressed on neuroendocrine tumors, is a validated target. Clesitamig is a trispecific antibody adding conditional 4-1BB costimulation to DLL3-targeted,CD3-dependent T-cell activation to improve on CD3 engagement alone while limiting of-tumor toxicity. A first-in-human phase 1 study evaluated clesitamig for advanced SCLC or other NEC. A total of 41 patients (26 SCLC, 15 other NEC) received clesitamig weekly or every 3 weeks at 0.03-50 mg, with a 1 mg single step-up priming dose, and target doses ≥ 3 mg. Cytokine release syndrome (CRS) was the most common treatment-related adverse event (19/41; 46.3%), all grade 1-2 (median onset 1 day, range 0-3; median duration 3 days range 1-7). A 1 mg step-up priming dose kept all CRS at grade ≤ 2 throughout escalation (maximum tolerated dose not reached) grade 2 CRS was more frequent with step-up than flat dosing, reflecting the higher doses reached. Events consistent with immune effector cell-associated neurotoxicity occurred in 6 patients (14.6%); all low-grade and reversible. Exposure increased approximately dose-proportionally, but antidrug antibodies developed in all patients treated for multiple cycles. Of 39 efficacy-evaluable patients, 6 had a confirmed partial response (15.4%; 95%CI 5.9-30.5) and 11 stable disease (disease control rate 43.6%; 27.8-60.4), predominantly in SCLC. Median duration of response was 4.1 months overall and 4.4 months in SCLC. The authors conclude that clesitamig had tolerable safety, manageable CRS, and clear pharmacodynamic activation. Immunogenicity limited long-term exposure in many patients, but preliminary antitumor activiy was encouraging (graphical abstract).

Original publicationjitc.bmj.com
Read the publication